This study is investigating a medication called orforglipron for women with stress urinary incontinence (SUI) who are either overweight or have obesity. SUI is when urine leaks during activities like coughing or exercising. The study lasts for about 58 weeks, which includes screening and safety follow-up.

• Duration: Participation is approximately 58 weeks.
• Eligibility: Must be female with a BMI of 27 or higher and have SUI.
• Exclusions: Recent surgery for incontinence, Botox injections, or weight fluctuations.

Participants cannot join if they've had certain medical conditions or treatments recently, like urinary incontinence surgery or using weight loss drugs, or if they have diabetes. Pregnant or breastfeeding women also cannot participate.